-
平臺(tái)編號(hào)：bio-129800
-
細(xì)胞信息： PaTu 8902
-
規(guī)格：1×10?cells/T25培養(yǎng)瓶
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類(lèi)或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
人胰腺癌細(xì)胞PaTu 8902
細(xì)胞名稱(chēng)：人胰腺癌細(xì)胞PaTu 8902
產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細(xì)胞數(shù)量：1x10^6；1x10^6
保存溫度：37℃；-198℃
運(yùn)輸方式：常溫保溫運(yùn)輸；干冰運(yùn)輸
安全等級(jí)：1
用途限制：僅供科研3類(lèi)
培養(yǎng)體系：DMEM高糖（HYCLONE SH30022.01)+10%FBS+1%三抗+200ug/ml IL2
培養(yǎng)溫度：37℃
二氧化碳濃度：5%
簡(jiǎn)介：人胰腺癌細(xì)胞PaTu 8902取自44歲女性。該細(xì)胞保藏于DSMZ。
注釋?zhuān)篜art of:Cancer Cell Line Encyclopedia(CCLE)project.
Part of:COSMIC cell lines project.
Part of:MD Anderson Cell Lines Project.
Part of:NCI RAS program mutant KRAS cell line panel.
Doubling time:~25-40 hours(DSMZ).
Microsatellite instability:Stable(MSS)(Sanger).
Omics:Array-based CGH.
Omics:Deep exome analysis.
Omics:Deep RNAseq analysis.
Omics:DNA methylation analysis.
Omics:Metabolome analysis.
Omics:Protein expression by reverse-phase protein arrays.
Omics:SNP array analysis.
Omics:Transcriptome analysis.
基因突變
Heterozygous for EP300 p.Ser1650Tyr(6148C>A)(PubMed=10700188;CCLE;Cosmic-CLP).
Heterozygous for KRAS p.Gly12Val(c.35G>T)(ClinVar=VCV000012583)(CCLE;Cosmic-CLP).
Homozygous for TP53 p.Cys176Ser(c.526T>A)(ClinVar=VCV000376570)(PubMed=10700188;CCLE;Cosmic-CLP).
HLA信息
/
STR信息
Amelogenin X
CSF1PO 10,11
D3S1358 16,18
D5S818 11,12
D7S820 8,10
D8S1179 13
D13S317 11,12
D16S539 9,11
D18S51 15
D21S11 30
FGA 23
Penta D 11
Penta E 12,15
TH01 9.3
TPOX 8
vWA 18
參考文獻(xiàn)
PubMed=29444439;DOI=10.1016/j.celrep.2018.01.051
Yuan T.L.,Amzallag A.,Bagni R.,Yi M.,Afghani S.,Burgan W.,Fer N.,Strathern L.A.,Powell K.,Smith B.,Waters A.M.,Drubin D.,Thomson T.,Liao R.,Greninger P.,Stein G.T.,Murchie E.,Cortez E.,Egan R.K.,Procter L.,Bess M.,Cheng K.T.,Lee C.-S.,Lee L.C.,Fellmann C.,Stephens R.,Luo J.,Lowe S.W.,Benes C.H.,McCormick F.
Differential effector engagement by oncogenic KRAS.
Cell Rep.22:1889-1902(2018)
PubMed=30894373;DOI=10.1158/0008-5472.CAN-18-2747
Dutil J.,Chen Z.,Monteiro A.N.,Teer J.K.,Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res.79:1263-1273(2019)
PubMed=31068700;DOI=10.1038/s41586-019-1186-3
Ghandi M.,Huang F.W.,Jane-Valbuena J.,Kryukov G.V.,Lo C.C.,McDonald E.R.III,Barretina J.,Gelfand E.T.,Bielski C.M.,Li H.,Hu K.,Andreev-Drakhlin A.Y.,Kim J.,Hess J.M.,Haas B.J.,Aguet F.,Weir B.A.,Rothberg M.V.,Paolella B.R.,Lawrence M.S.,Akbani R.,Lu Y.,Tiv H.L.,Gokhale P.C.,de Weck A.,Mansour A.A.,Oh C.,Shih J.,Hadi K.,Rosen Y.,Bistline J.,Venkatesan K.,Reddy A.,Sonkin D.,Liu M.,Lehar J.,Korn J.M.,Porter D.A.,Jones M.D.,Golji J.,Caponigro G.,Taylor J.E.,Dunning C.M.,Creech A.L.,Warren A.C.,McFarland J.M.,Zamanighomi M.,Kauffmann A.,Stransky N.,Imielinski M.,Maruvka Y.E.,Cherniack A.D.,Tsherniak A.,Vazquez F.,Jaffe J.D.,Lane A.A.,Weinstock D.M.,Johannessen C.M.,Morrissey M.P.,Stegmeier F.,Schlegel R.,Hahn W.C.,Getz G.,Mills G.B.,Boehm J.S.,Golub T.R.,Garraway L.A.,Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)
細(xì)胞操作說(shuō)明下載：細(xì)胞操作說(shuō)明
產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細(xì)胞數(shù)量：1x10^6；1x10^6
保存溫度：37℃；-198℃
運(yùn)輸方式：常溫保溫運(yùn)輸；干冰運(yùn)輸
安全等級(jí)：1
用途限制：僅供科研3類(lèi)
培養(yǎng)體系：DMEM高糖（HYCLONE SH30022.01)+10%FBS+1%三抗+200ug/ml IL2
培養(yǎng)溫度：37℃
二氧化碳濃度：5%
簡(jiǎn)介：人胰腺癌細(xì)胞PaTu 8902取自44歲女性。該細(xì)胞保藏于DSMZ。
注釋?zhuān)篜art of:Cancer Cell Line Encyclopedia(CCLE)project.
Part of:COSMIC cell lines project.
Part of:MD Anderson Cell Lines Project.
Part of:NCI RAS program mutant KRAS cell line panel.
Doubling time:~25-40 hours(DSMZ).
Microsatellite instability:Stable(MSS)(Sanger).
Omics:Array-based CGH.
Omics:Deep exome analysis.
Omics:Deep RNAseq analysis.
Omics:DNA methylation analysis.
Omics:Metabolome analysis.
Omics:Protein expression by reverse-phase protein arrays.
Omics:SNP array analysis.
Omics:Transcriptome analysis.
基因突變
Heterozygous for EP300 p.Ser1650Tyr(6148C>A)(PubMed=10700188;CCLE;Cosmic-CLP).
Heterozygous for KRAS p.Gly12Val(c.35G>T)(ClinVar=VCV000012583)(CCLE;Cosmic-CLP).
Homozygous for TP53 p.Cys176Ser(c.526T>A)(ClinVar=VCV000376570)(PubMed=10700188;CCLE;Cosmic-CLP).
HLA信息
/
STR信息
Amelogenin X
CSF1PO 10,11
D3S1358 16,18
D5S818 11,12
D7S820 8,10
D8S1179 13
D13S317 11,12
D16S539 9,11
D18S51 15
D21S11 30
FGA 23
Penta D 11
Penta E 12,15
TH01 9.3
TPOX 8
vWA 18
參考文獻(xiàn)
PubMed=29444439;DOI=10.1016/j.celrep.2018.01.051
Yuan T.L.,Amzallag A.,Bagni R.,Yi M.,Afghani S.,Burgan W.,Fer N.,Strathern L.A.,Powell K.,Smith B.,Waters A.M.,Drubin D.,Thomson T.,Liao R.,Greninger P.,Stein G.T.,Murchie E.,Cortez E.,Egan R.K.,Procter L.,Bess M.,Cheng K.T.,Lee C.-S.,Lee L.C.,Fellmann C.,Stephens R.,Luo J.,Lowe S.W.,Benes C.H.,McCormick F.
Differential effector engagement by oncogenic KRAS.
Cell Rep.22:1889-1902(2018)
PubMed=30894373;DOI=10.1158/0008-5472.CAN-18-2747
Dutil J.,Chen Z.,Monteiro A.N.,Teer J.K.,Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res.79:1263-1273(2019)
PubMed=31068700;DOI=10.1038/s41586-019-1186-3
Ghandi M.,Huang F.W.,Jane-Valbuena J.,Kryukov G.V.,Lo C.C.,McDonald E.R.III,Barretina J.,Gelfand E.T.,Bielski C.M.,Li H.,Hu K.,Andreev-Drakhlin A.Y.,Kim J.,Hess J.M.,Haas B.J.,Aguet F.,Weir B.A.,Rothberg M.V.,Paolella B.R.,Lawrence M.S.,Akbani R.,Lu Y.,Tiv H.L.,Gokhale P.C.,de Weck A.,Mansour A.A.,Oh C.,Shih J.,Hadi K.,Rosen Y.,Bistline J.,Venkatesan K.,Reddy A.,Sonkin D.,Liu M.,Lehar J.,Korn J.M.,Porter D.A.,Jones M.D.,Golji J.,Caponigro G.,Taylor J.E.,Dunning C.M.,Creech A.L.,Warren A.C.,McFarland J.M.,Zamanighomi M.,Kauffmann A.,Stransky N.,Imielinski M.,Maruvka Y.E.,Cherniack A.D.,Tsherniak A.,Vazquez F.,Jaffe J.D.,Lane A.A.,Weinstock D.M.,Johannessen C.M.,Morrissey M.P.,Stegmeier F.,Schlegel R.,Hahn W.C.,Getz G.,Mills G.B.,Boehm J.S.,Golub T.R.,Garraway L.A.,Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)
細(xì)胞操作說(shuō)明下載：細(xì)胞操作說(shuō)明
